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Background: Impaired lung function is an independent predictor of cardiovascular mortality.
We assessed the relationships of lung function with insulin resistance (IR), metabolic syndrome
(MetS), systemic inflammation and coronary artery calcification score (CACS) measured by
computed tomography (CT) scan an indicator of coronary atherosclerosis.
Methods: We identified 4905 adult male patients of the Health Promotion Center in Samsung
Medical Center between March 2005 and February 2008 and retrospectively reviewed the
following data for these patients: pulmonary function, CT-measured CACS, anthropometric
measurement, fasting glucose, insulin, lipid profiles, serum C-reactive protein (CRP) and
homeostatic model assessment (HOMA-IR). MetS was defined according to the AHA/NHLBI
criteria.
Results: When the subjects were divided into four groups according to quartiles of FVC or FEV1
(% pred), serum CRP level, HOMA-IR, prevalence of MetS and CACS significantly increased as
the FVC or FEV1 (% pred) decreased. The odds ratios (ORs) for MetS in the lowest quartiles3410 3429; fax: þ82 2 3410 6956.
.Y. Suh).
to the research and writing of this paper.
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Lung function, coronary artery calcification, and metabolic syndrome 1327of FVC and FEV1 (% pred) were 1.85 (95% CI, 1.49e2.30; p< 0.001) and 1.47 (95% CI, 1.20e1.81;
p< 0.001) respectively. The ORs for the presence of coronary artery calcification in the lowest
quartiles of FVC and FEV1 (% pred) were 1.31 (95% CI, 1.09e1.58; pZ 0.004) and 1.22 (95% CI,
1.02e1.46; pZ 0.029) respectively. Obesity, CRP, HOMA-IR, and the presence of coronary
artery calcium were independent risk predictors for impaired lung function.
Conclusion: Metabolic syndrome, insulin resistance, coronary atherosclerosis, and systemic
inflammation are closely related to the impaired lung function.
ª 2010 Elsevier Ltd. All rights reserved.From Mar. 2005 to Feb. 2008
6,446 visits 40years with CT for CACS
5,139 visits
1,307 without PFT or Parameters of 
MetS were excluded.
79 with previous history of CHD and 4 with 
inflammatory disease were excluded.
4,905 participants
151 had more than one visit 
during this period*
5,056 visits
Figure 1 Study flow diagram. CACS, coronary artery calcifi-
cation score; PFT, pulmonary function test; MetS, Metabolic
Syndrome; CVD, cardiovascular disease. *Maximum number of
visits the patient had was twice.Introduction
Impaired lung function, as measured by forced vital
capacity (FVC) or forced expiratory volume (FEV1), is
associated with increased incidence and mortality of
cardiovascular diseases (CVD).1e5 Although the mechanisms
underlying this association are unknown, it cannot be
explained only by the effects of smoking. Several previous
studies have suggested that there is a link between
impaired lung function and CVD-related factors such as
obesity, insulin resistance (IR) or atherosclerosis.6e9
Previous approaches exploring the association between
lung function and atherosclerosis used carotid intima-
media thickness for the noninvasive evaluation of athero-
sclerosis.10 Recently, the coronary artery calcium score
(CACS) measured by computed tomography (CT) has been
frequently used to assess the atherosclerotic plaque
burden.11e13 CACS is a well-accepted, reliable tool for
predicting future coronary artery disease.14
In addition to associations with individual risk factors,
several recent studies have found a positive independent
correlation between impaired lung function and metabolic
syndrome (MetS).15e17 However, it is not known whether
this relationship holds true in patients with normal lung
function.
The objective of this study was to assess the relationship
of decreased lung function with a focus on coronary artery
calcification, MetS, and other metabolic and inflammatory




This study was approved by the Institutional Review Board
of Samsung Medical Center, and the requirement for
patient consent was waived given the retrospective nature
of the study.
Data from patients who participated in the annual
medical check-up program of the Health Promotion Centre
in Samsung Medical Center (a 1250-bed tertiary university
hospital in Seoul, South Korea) between March 2005 and
February 2008 was used for this study. Inclusion criteria
were male gender, age> 40 years, availability of CACS on
coronary CT, data to assess the presence of MetS, and data
to assess lung function. A total of 5,139 Korean men aged
more than 40 years met these criteria. Medical information
was gathered through a standardized questionnaire and
we excluded subjects with severe cardiovascular disease(nZ 79), documented acute pharyngitis (nZ 2), inflam-
matory bowel disease (nZ 1), and autoimmune disease
(nZ 1). Current or past smokers were classified as smokers.
When the person had more than one visit during this period
(nZ 151, the maximum number of visits the patient had
was twice), only the data from the last visit was analyzed.
Analysis was performed on a total of 4905 subjects (Fig. 1).
During study period, female subjects who met the criteria
of our study were only 673, since the CT for CACS is
recommended usually for men over 40 years. Considering
selection bias, we excluded the data of female subjects.
Measurement of lung function
Spirometrywas performedas recommended by the American
Thoracic Society18 using Vmax 22 (SensorMedics, OH, USA).
Absolute values of FVC and FEV1 were obtained and
percentage predicted values (% pred) for FEV1 and FVC were
calculated from the following equations obtained in
a representative Korean sample.19
Predicted FVCZ  4:8434  ð0:00008633  age2ðyearsÞÞ
þ ð0:05292  heightðcmÞÞ þ ð0:01095  weightðkgÞÞ
Predicted FEV1Z  3:4132  ð0:0002484  age2ðyearsÞÞ
þ ð0:04578  heightðcmÞÞ
The highest FVC and FEV1 value of the three or more
tests with acceptable curves was used.




Age, years 51 (47e57)
Smoking status
None, % 21.8
Current or past, % 78.2
BMI 25(kg/m2), % 45.3
Laboratory test
WBC (103/ml) 5750 (4860e6800)
CRP (mg/dl) (nZ 4779) 0.07 (0.03e0.13)
FBG (mg/dl) 92 (85e100)
Insulin (mIU/mL) 9.1 (7.1e11.8)
Total cholesterol (mg/dl) 192 (171e214)
LDL-cholesterol (mg/dl) 126 (107e145)
HDL-cholesterol (mg/dl) 51 (44e59)
Triglyceride (mg/dl) 129 (94e185)
Metabolic syndrome, % 23.0
Waist circumference 90 cm, % 38.9
Low HDL cholesterol< 40 mg/dL
or specific treatment,%
13.2
Triglycerides 150 mg/dL or
specific treatment,%
37.9
SBP 130/DBP 85mmHg or
antihypertensive treatment,%
36.8
Fasting glucose 100 mg/dL or
diabetes treatment,%
27.3
HOMA-IR (nZ 3861) 2.1 (1.6e2.9)
Pulmonary function test
FEV1/FVC ratio,% 80 (76e84)
FVC % pred 86 (79e93)
FEV1% pred 88 (80e95)
Coronary artery calcification
A-CACS mean (interquartile range) 42.8 (0.0e15.3)
Presence of coronary artery
calcification, (A-CACS> 0) %
37.2
Values are expressed as percentages, or median (interquartile
range). BMI, body mass index; WBC, white blood cell; CRP,
C-reactive protein; LDL, low-density lipoprotein; HDL, high-
density lipoprotein; HOMA-IR, homeostatic model assessment-
insulin resistance; FEV1, forced expiratory volume in 1 s; FVC,
forced vital capacity; A-CACS, Agaston coronary artery calcifi-
cation score.
1328 H.Y. Park et al.We analyzed the patients according to the quartiles of
FVC or FEV1 (%pred), and ventilatory patterns defined as
restrictive (FEV1/FVC 70% and FVC< 80%) or obstructive
(FEV1/FVC< 70%) pattern.
Coronary Artery Calcification Score (CACS)
Imaging data for the evaluation of coronary artery calcifi-
cation was acquired from an ECG-gated 40 channel multi-
detector CT scanner (Brilliance 40, EBW version 3.02 RRS,
Philips Medical Systems, Best, The Netherlands), with a 400
milliseconds gantry rotation time and image reconstructionthickness/interval 2.5 mm/2.5 mm. Agaston coronary
artery calcium score (A-CACS) was used for the measure-
ment of CACS.20 The area of coronary artery calcium was
defined as at least four contiguous pixels with a CT density
130 Hounsfield Units. The total CACS was computed,
comprising all calcified lesions in the epicardial coronary
system.
Anthropometric measurements and blood tests
Height, weight, waist circumference (WC), systolic (SBP)
and diastolic blood pressure (DBP) were measured. Blood
pressure was measured according to the Hypertension
Detection and Follow-Up Program protocol by using
a mercury blood pressure device after the subjects had
rested for more than five minutes.21 For subjects with a SBP
higher than 140 mmHg and a DBP higher than 90 mmHg, BP
was measured two more times after resting and the average
value was used. Height and weight were measured by
automatic scale, and body mass index (BMI) was calculated
by weight (kg) divided by the squared value of height (m)
(kg/m2). WC was measured at the part of the trunk located
midway between the lower costal margin (bottom of lower
rib) and the iliac crest (top of pelvic bone) while the patient
was standing.
After a 12 h fast, fasting blood glucose (FBG) with the
hexokinase method, CRP with turbid immunoassay, total
cholesterol (TC), triglyceride (TG) with the enzymatic
colorimetric method, high-density lipoprotein cholesterol
(HDL-C) with the modified enzymatic method and low-
density lipoprotein-cholesterol (LDL-C) with the direct
surfactant method were automatically measured using an
autoanalyzer (Hitachi, Modular D 2400; Tokyo, Japan).
Fasting serum insulin levels were measured by the
electrochemiluminescence immunoassay (Hitachi, Roche
Modular E 170; Tokyo, Japan), with an intra-assay coeffi-
cient of variance of 0.9e1.2% and an inter-assay coefficient
of variance of 3.4e4.9%.
IR status was calculated by using the homeostatic model
assessment-insulin resistance (HOMA-IR).22 The calculation
formula was as follows:
HOMA IRZ ½fasting insulin ðmIU=mLÞ
 fasting blood glucose ðmmol=LÞ=22:5
Diagnosis of Metabolic Syndrome (MetS)
MetS was defined based on the American Heart Association/
National Heart, Lung, and Blood Institute (AHA/NHLBI) with
WC defined by the Western Pacific Region of WHO for
obesity (WPRO) criteria.23 The diagnosis of MetS was made
when the subjects satisfied more than three of the five
categories described below23:
1. Abdominal obesity: WC 90 cm;
2. Hypertriglyceridaemia: 150 mg/dL (1.7 mmol/L);
3. Low HDL-C: <40 mg/dL (1.0 mmol/L);
4. Hypertension: 130/85 mmHg; and
5. Fasting hyperglycaemia: 100 mg/dL (5.6 mmol/L).
Table 2 Comparisons of HOMA-IR, CRP values, coronary artery calcification score, and prevalence of the metabolic syndrome according to the quartiles of FVC % of
predicted value.









p Value for trend
Age, years 55 (50e62) 52 (48e57) 50 (47e55) 49 (46e53) <0.001
Smoker (%) 80.0 77.6 79.0 76.6 0.108
BMI 25 kg/m2, % 55.0 48.4 43.2 35.8 <0.001
Laboratory test
WBC (103/ml) 6000 (5100e7100) 5765 (4900e6900) 5740 (4900e6700) 5500 (4700e6600) <0.001



















A-CACS (mean) 72.2 40.8 38.0 24.1 <0.001
Presence of coronary artery
calcification (A-CACS >0),%
49.4 38.8 33.7 28.5 <0.001
Components of Metabolic Syndrome
Waist circumference 90 cm, % 52.9 41.9 35.5 27.0 <0.001
Low HDL cholesterol< 40 mg/dL or
specific treatment, %
14.2 15.3 12.1 11.2 0.004
Triglycerides 150 mg/dL or
specific treatment, %
42.1 41.4 38.2 30.6 <0.001
SBP 130/DBP 85 mmHg or
antihypertensive treatment, %
46.2 39.5 34.1 28.6 <0.001
Fasting glucose 100 mg/dL or
diabetes treatment, %
34.5 28.9 25.1 21.4 <0.001
Values are expressed as percentages, or median (interquartile range).
FVC, forced vital capacity; BMI, body mass index; WBC, white blood cell; CRP, C-reactive protein; HOMA-IR, homeostatic model assessment-insulin resistance; A-CACS, Agaston coronary

















































p Value for trend
ge, year 54 (49e60) 51 (47e56) 50 (47e55) 50 (47e55) <0.001
oker, % 83.9 77.9 77.9 73.9 <0.001
I 25 kg/m2 ,% 45.8 45.7 45.3 44.4 0.483
boratory test
WBC (103/ml) 6050 (5100e7200) 5800 (4900e6900) 5700 (4800e6700) 5540 (4700e6500) <0.001



















A-CACS (mean) 67.7 37.5 36.1 32.9 <0.001
Presence of coronary artery
calcification (A-CACS> 0),%
46.9 35.7 33.9 33.3 <0.001
omponents of Metabolic Syndrome
Waist circumference 90 cm,% 44.7 41.8 37.8 32.0 <0.001
Low HDL cholesterol< 40 mg/dL or
specific treatment, %
13.6 14.1 12.6 12.4 0.246
Triglycerides 150 mg/dL or
specific treatment, %
41.0 40.9 37.5 32.8 <0.001
SBP 130/DBP 85 mmHg or
antihypertensive treatment, %
41.7 38.1 33.4 34.3 <0.001
Fasting glucose 100 mg/dL or
diabetes treatment, %
31.0 27.6 27.2 23.8 <0.001
lues are expressed as percentages, or median (interquartile range).
C, forced vital capacity; BMI, body mass index; WBC, white blood cell; CRP, C-reactive protein; HOMA-IR, homeostatic model assessment-insulin resistance; A-CACS, Agaston coronary






















Figure 2 A and B. The prevalence of metabolic syndrome
according to decrement of FVC% pred and FEV1% pred.
Lung function, coronary artery calcification, and metabolic syndrome 1331Because obesity is defined as BMI 25 kg/m2 in Asian
populations, BMI in our study was divided with a cut-off
point of 25 kg/m2 for obesity.24
Data analysis
To assess whether there was a gradient in various clinical
characteristics and laboratory test results across the
pulmonary function categories, we used a ManteleHaenszel
test or JonckheereeTerpstra trend test. Using the highest
quartile as the reference group in multivariate logistic
regression model, we compared the prevalence of MetS,
the individual components of MetS, and the presence of
coronary artery calcification across the quartiles of FEV1
(% pred) and FVC (% pred) after adjustment for confounding
factors including age, smoking status and BMI. Among the
components of MetS, dyslipidemia was defined as a combi-
nation of two components e HDL-C< 40 mg/dL or specific
treatment for this lipid abnormality and triglycer-
ides 150 mg/dL or specific treatment for this lipid
abnormality. Because the distribution of CRP level was
highly skewed, log10-transformed CRP (log10 CRP) values
were used for the multivariate analysis.
Values are expressed as percentage of patients or
median value (interquartile range). Two-sided p-values less
than 0.05 were considered statistically significant. SPSS
version 11.0 (SPSS Inc, Chicago, IL, USA) and SAS version 9.1
(SAS Institute; Cary, NC, USA) were used for computational
analysis.
Results
Clinical characteristics of the study population
The clinical characteristics of the participants are shown in
Table 1. Among 4905 study participants in this analysis, the
median age (interquartile range) was 51 (47e57) years and
78.2% were current or ex-smokers. The prevalence of MetS
was 23.0%. The median (interquartile range) values for the
FBG, fasting insulin, and CRP were 92 (85e100) mg/dL, 9.1
(7.1e11.8) mIU/mL, and 0.07 (0.03e0.13) mg/L respec-
tively. Coronary artery calcification was present in 37.2%
and the mean A-CACS was 42.8.
Comparisons of HOMA-IR, CRP values, coronary
artery calcification score, and the prevalence of
the metabolic syndrome according to the quartiles
of FVC and FEV1 % of predicted value
We classified patients according to the quartiles of FVC or
FEV1 (% pred) (Table 2 and 3).
When subjects were grouped by quartiles of FVC or FEV1
(% pred), median HOMA-IR values significantly increased as
the FVC or FEV1 (% pred) decreased from the fourth quartile
to the first quartile. Patients in the lowest FEV1 or FVC
quartiles (Quartile 1) had a significantly higher CRP
concentration compared with the other three groups
(Quartiles 2, 3, 4). The frequency of coronary artery
calcification (A-CACS> 0) as well as the mean values of
A-CACS increased as the quartiles of FVC and FEV1 (% pred)decreased from the fourth quartile to the first quartile
(p< 0.001, both).
The prevalence of MetS tended also to increase signifi-
cantly according to the decrement of quartile of FVC (%
pred) and FEV1 (% pred) (Fig. 2A and B) and consistently, the
frequency of the individual components of MetS signifi-
cantly increased as FEV1 (% pred) and FVC (% pred) quartiles
decreased. The one exception was HDL-C in FEV1 (% pred)
quartiles.
Odds ratios for the risk of metabolic syndrome and
coronary artery calcification according to quartiles
of FVC and FEV1 % of predicted value adjusted for
age, smoking status, and BMI
As shown in Table 4, after adjustment for age, smoking
status and BMI, the odds ratio for MetS in the lowest
1332 H.Y. Park et al.quartile of FVC (% pred) and FEV1 (% pred) was 1.85 (95% CI,
1.49e2.30; p< 0.001) and 1.47 (95% CI, 1.20e1.81;
p< 0.001) respectively, when the highest quartile was
considered as 1.
The odds ratio for the presence of coronary artery
calcification (A-CACS> 0) in the lowest quartile of FVC
(% pred) and FEV1 (% pred) was 1.31 (95% CI, 1.09e1.58;
pZ 0.004) and 1.22 (95% CI, 1.02e1.46; pZ 0.029)
respectively, when the highest quartile was considered as 1
(Table 4).
Multiple logistic regression analyses with the lowest
quartile of lung function or ventilator pattern as
the dependent variable
Multiple logistic regression analyses with the adjusted
model (age, smoking status, BMI) were developed to
determine the relationship between abdominal obesity,
CRP, HOMA-IR, and the presence of coronary artery calci-
fication and the presence of the lowest FVC and FEV1
(% pred) quartile as a dependent variable. Our analyses
showed that obesity, higher CRP, higher HOMA-IR, and the
presence of coronary artery calcification were independent
predictors of the lowest FVC and FEV1 (% pred) quartiles
(Table 5).
In multiple logistic regression analysis with the adjusted
model (age, smoking status, BMI) performed for restrictive
pattern (nZ 1154) and obstructive pattern (nZ 306) as
a dependent variable, the central obesity and the presence
of coronary artery calcification were an independent factor
associated with both restrictive (adjusted OR 1.55, 95% CI
1.26e1.91; p< 0.001 and adjusted OR 1.40, 95% CI 1.18e
1.66; p< 0.001) and obstructive patterns (adjusted OR 1.72
95% CI 1.18e2.50; pZ 0.005 and adjusted OR 1.37, 95% CI
1.01e1.87; pZ 0.042). The higher CRP was an independentTable 4 Odds ratios (95% confidence interval) for the risk of me
to the quartile of FVC and FEV1% of predicted value adjusting ag
FVC (% pred) quartiles
1st 2nd
Metabolic syndrome 1.85 (1.49e2.30)* 1.68 (
Abdominal obesity (90 cm) 2.17 (1.73e2.71)* 1.54 (
Dyslipidemia 1.67 (1.40e1.99)* 1.50 (
Impaired glucose metabolism 1.47 (1.22e1.79)* 1.32 (
Elevated blood pressure 1.43 (1.19e1.71)* 1.35 (
Presence of coronary artery
calcification (A-CACS >0)
1.31 (1.09e1.58)* 1.23 (
FEV1(% pred) quartiles
Metabolic syndrome 1.47 (1.20e1.81)* 1.34 (
Abdominal obesity (90 cm) 1.85 (1.49e2.29)* 1.73 (
Dyslipidemia 1.45 (1.22e1.71)* 1.39 (
Impaired glucose metabolism 1.23 (1.02e1.48)* 1.18 (
Elevated blood pressure 1.14 (0.96e1.36) 1.16 (
Presence of coronary artery
calcification (A-CACS >0)
1.22 (1.02e1.46)* 1.04 (
A-CACS, Agaston coronary artery calcification score.
*p< 0.05.factor in only obstructive pattern (adjusted OR 1.45, 95% CI
1.01e2.08; pZ 0.042), while the higher HOMA-IR was
significantly associated with only restrictive pattern
(adjusted OR 1.19, 95% CI 1.11e1.27; p< 0.001).
Discussion
The major findings of this study are that as lung function
decreases in Korean men without cardiovascular events
over 40 years old, there are significant increases in CACS,
MetS, IR and serum CRP. Multiple logistic regression analysis
also revealed that the presence of coronary artery calcifi-
cation, obesity, IR, and CRP are independent risk predictors
for the lowest quartile of lung function. These results
indicate that lung function, coronary atherosclerosis, MetS,
IR, and serum CRP are closely related.
Our study is the first study to use CACS on coronary CT to
demonstrate associations between coronary atherosclerosis
and reduced lung function in a large population of subjects.
Prior studies used carotid atherosclerotic plaque as an
indicator of subclinical atherosclerosis.9,10 Radiographically
detectable coronary artery calcification has been known to
represent atherosclerotic plaque burden25 and numerous
clinical studies have confirmed that coronary artery calci-
fication is a strong marker of subclinical coronary artery
disease.11e13 In addition, a prospective cohort study of
subjects over four ethnic groups reported that CACS is
better than carotid intima-media thickness in predicting
subsequent cardiovascular disease events.14
In this study, we found a significant inverse relationship
between lung function and CACS or the presence of coro-
nary artery calcification. Furthermore, the odds ratios for
the presence of coronary artery calcification in the lowest
quartiles of FVC (% pred) and FEV1 (% pred) were signifi-
cantly higher than those in other quartiles even aftertabolic syndrome and coronary artery calcification according
e, smoking status and BMI.
3rd 4th p Value for
trend
1.36e2.07)* 1.28 (1.03e1.60)* 1 <0.001
1.25e1.90)* 1.29 (1.04e1.59)* 1 <0.001
1.27e1.77)* 1.30 (1.11e1.53)* 1 <0.001
1.09e1.58)* 1.15 (0.95e1.38) 1 <0.001
1.14e1.61)* 1.19 (1.00e1.41) 1 <0.001
1.03e1.46)* 1.14 (0.95e1.36) 1 0.003
1.10e1.64)* 1.24 (1.005e1.52)* 1 <0.001
1.41e2.13)* 1.37 (1.11e1.69)* 1 <0.001
1.18e1.63)* 1.15 (0.98e1.36) 1 <0.001
0.99e1.41) 1.19 (0.99e1.43) 1 0.044
0.98e1.36) 0.97 (0.82e1.15) 1 0.044
0.88e1.24) 1.03 (0.87e1.24) 1 0.036
Table 5 Multiple logistic regression analysis with lowest quartile of FVC and FEV1 % of predicted value as dependent variable.
NZ 3736 Lowest quartile of FVC (% pred) Lowest quartile of FEV1 (% pred)
Adjusted ORa(95% CI) p Value Adjusted ORa(95% CI) p Value
Abdominal obesity (WC 90 cm) 1.57 (1.27e1.93) <0.001 1.29 (1.05e1.59) 0.014
Log10 CRP 1.37 (1.11e1.69) 0.003 1.52 (1.24e1.85) <0.001
HOMA-IR 1.16 (1.09e1.24) <0.001 1.08 (1.02e1.15) 0.013
Presence of coronary artery
calcification (A-CACS> 0)
1.41 (1.19e1.67) <0.001 1.36 (1.15e1.61) <0.001
WC, waist circumference; CRP, C-reactive protein; HOMA-IR, homeostatic model assessment-insulin resistance; A-CACS, Agaston
coronary artery calcification score; OR, odds ratios; CI, confidence interval.
a Adjusted for age, smoking status and body-mass index.
Lung function, coronary artery calcification, and metabolic syndrome 1333adjustments for confounding factors including age, smoking
status, BMI, central obesity, CRP and IR. These findings
imply that reduced lung function and coronary atheroscle-
rosis are closely linked.
Another important finding of this study is that, even in
patients with predominantly ‘‘normal’’ lung function, there
was a statistically significant inverse relationship between
lung function and various risk factors for CVD including
MetS. In earlier reports on lung function and MetS, inves-
tigators focused on restrictive lung impairment.16,17,26 In
a recent population-based study, Leone et al.15 showed
a positive independent relationship between lung function
impairment (both obstructive and restrictive pattern) and
MetS, with abdominal obesity playing a critical role. The
findings of Leone et al. is compatible with the result of our
study, which central obesity is an independently associated
factor with both restrictive and obstructive patterns even
after adjustment for other cardiovascular factors, but, the
present study goes one step further showing a clear trend of
increasing prevalence of MetS with decreasing lung function
in Korean men without cardiovascular event. A number of
other studies assessed the relationship between CVD-
related factors and impaired lung function.3,6,8,27e29 Sin
et al.3 showed that even a modest decline in FEV1 (% pred)
from a mean of 109e88% was associated with a fivefold
increase in CVD mortality. Another study by Lawlor et al.8
demonstrated that IR assessed by HOMA score decreased
by 5% for a one standard deviation increase in log FEV1 and
by 8% for a one standard deviation increase in log FVC. Our
data suggests that these trends hold true even in patients
who have lung function in the ‘‘normal’’ range.
The association between the lung function and cardiac
risk factors becomes vividly clear when the lowest quartile
and the highest quartile of lung function was compared.
Based on our result, the frequency of cardiac risk factors
such as central obesity, dyslipidemia, impaired glucose
metabolism were significantly higher in the individuals with
the lowest quartile of lung function, which helps to esti-
mate that the individuals with the lowest quartile of lung
function have more cardiovascular risk than those with the
highest quartile of lung function. To predict the 10-year
cardiovascular risk, we have calculated Framingham Risk
Score (FRS) with factors such as age, smoking, cholesterol,
HDL-C, blood pressure and the presence of diabetes in
individuals with age< 75 years.30 The result from the
calculated FRS was significantly higher in those with thelowest quartile of lung function than those with the highest
quartile of lung function (10% vs. 7% in FVC (% pred);
p< 0.001 and 10% vs. 8% in FEV1 (% pred); p< 0.001).
However, further studies will be necessary to evaluate
whether subjects in the lowest quartile of lung function
experience a higher incidence of coronary events.
Although the mechanism underlying the relationship
between lung function and coronary atherosclerosis, MetS,
IR, obesity and CRP remains unclear, there are some plau-
sible explanations. First, the abnormal lung function
observed in obese patients may be explained by decreased
chest wall compliance and increased peripheral airway
resistance.6 In addition to mechanical factors, adipose
tissue is thought be a major source of proinflammatory
cytokines and may play an essential role in producing low-
grade systemic inflammation.6,31 It has been reported that
the inflammatory biomarker represented by CRP was asso-
ciated with obstructive or restrictive lung disease as well as
obesity.32,33 Also, the relationship between elevated CRP
levels and MetS or IR has been documented.34,35 Taken
together, these reports suggest that systemic inflammation
may be an element in the link between lung function
impairment and obesity, IR, and MetS. However, it is diffi-
cult to draw clear conclusions about a causal relationship
based only on the results of this study.
This study has several limitations. It was a retrospective
study performed on individuals who voluntarily visited our
center for health examinations. Thus, time-dependent
relationships between altered WC or coronary artery
calcification and pulmonary function could not be
observed. Second, because coronary CT was performed in
men over 40 years who wanted detailed evaluation for
coronary artery disease, our study could reflect some
selection bias. However, such selection bias would be low
because we excluded men with current or previous histories
of angina or myocardial infarction by medical history and
the prevalence of metabolic syndrome was similar to
prevalence reported in the Korean National Health and
Nutrition Examination Surveys (KNHANES).36 Finally, the
present study was conducted at a single center with only
male subjects, which might have an influence on the
generalization of its findings.
In conclusion, this study clearly showed that coronary
atherosclerosis, metabolic syndrome, insulin resistance,
and systemic inflammation are closely related to the
decreased lung function.
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